{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Tumour&page=38", "query": { "condition": "Advanced Solid Tumour", "page": 38 }, "page_size": 10 }, "pagination": { "page": 38, "page_size": 10, "total_count": 3367, "total_pages": 337, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Tumour&page=39&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Tumour&page=37&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T09:56:24.761Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00729664", "title": "Multiple Ascending Dose (MDX1105-01)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer, Multiple Indications" ], "interventions": [ { "name": "Anti-PDL-1 antibody", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 281, "start_date": "2009-02", "completion_date": "2015-07", "has_results": false, "last_update_posted_date": "2015-09-07", "last_synced_at": "2026-10-16T09:56:24.761Z", "location_count": 11, "location_summary": "Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00729664" }, { "nct_id": "NCT04015609", "title": "Psychotherapy Intervention for Latinos With Advanced Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Solid Tumor", "Solid Tumor, Adult", "Solid Tumor, Unspecified, Adult" ], "interventions": [ { "name": "Meaning Centered Psychotherapy for Latinos", "type": "BEHAVIORAL" }, { "name": "Functional Assessment of Cancer Therapy - Spiritual Well-Being Scale", "type": "BEHAVIORAL" }, { "name": "Meaning Centered Psychotherapy for Latinos for Waitlist Control Patients", "type": "BEHAVIORAL" }, { "name": "Pre-assessment questionnaire", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 177, "start_date": "2015-04-20", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-16T09:56:24.761Z", "location_count": 3, "location_summary": "New York, New York • The Bronx, New York", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04015609" }, { "nct_id": "NCT03836352", "title": "Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Hepatocellular Carcinoma", "Non-small Cell Lung Cancer", "Bladder Cancer", "Microsatellite Instability-High" ], "interventions": [ { "name": "DPX-Survivac", "type": "OTHER" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "ImmunoVaccine Technologies, Inc. (IMV Inc.)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 184, "start_date": "2018-12-21", "completion_date": "2023-12-31", "has_results": false, "last_update_posted_date": "2022-03-31", "last_synced_at": "2026-10-16T09:56:24.761Z", "location_count": 15, "location_summary": "Tucson, Arizona • Los Angeles, California • Boca Raton, Florida + 12 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Port Saint Lucie", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03836352" }, { "nct_id": "NCT01245543", "title": "Safety Study for Intravenous (IV) AC480 (AC480IV) to Treat Advanced Solid Tumors", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "AC480IV", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2010-11", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2015-11-02", "last_synced_at": "2026-10-16T09:56:24.761Z", "location_count": 2, "location_summary": "San Francisco, California • San Antonio, Texas", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01245543" }, { "nct_id": "NCT04973163", "title": "A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors, KRAS Mutation" ], "interventions": [ { "name": "BI 1823911", "type": "DRUG" }, { "name": "BI 1701963", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2021-09-09", "completion_date": "2026-12-27", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-16T09:56:24.761Z", "location_count": 3, "location_summary": "New York, New York • Dallas, Texas • Houston, Texas", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04973163" }, { "nct_id": "NCT04348916", "title": "Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer", "Melanoma", "Solid Tumor", "Squamous Cell Carcinoma of Head and Neck", "Breast Cancer", "Advanced Solid Tumor", "Triple Negative Breast Cancer", "Colorectal Carcinoma", "Non-melanoma Skin Cancer", "Liver Metastases" ], "interventions": [ { "name": "ONCR-177", "type": "BIOLOGICAL" }, { "name": "pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Oncorus, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2020-05-20", "completion_date": "2023-05-31", "has_results": false, "last_update_posted_date": "2023-06-08", "last_synced_at": "2026-10-16T09:56:24.761Z", "location_count": 10, "location_summary": "Duarte, California • Denver, Colorado • Tampa, Florida + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04348916" }, { "nct_id": "NCT03261947", "title": "A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Cancer", "Colorectal Cancer", "Esophageal Neoplasms", "Carcinoma, Non-small-cell Lung" ], "interventions": [ { "name": "TAK-931", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 101, "start_date": "2017-10-25", "completion_date": "2020-08-24", "has_results": true, "last_update_posted_date": "2021-09-20", "last_synced_at": "2026-10-16T09:56:24.761Z", "location_count": 8, "location_summary": "Denver, Colorado • Sarasota, Florida • Minneapolis, Minnesota + 5 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT03261947" }, { "nct_id": "NCT01538537", "title": "Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer", "Solid Tumors", "Cancer", "Neoplasms" ], "interventions": [ { "name": "rigosertib sodium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Traws Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2006-08", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2017-06-23", "last_synced_at": "2026-10-16T09:56:24.761Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01538537" }, { "nct_id": "NCT07107230", "title": "A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Stage Solid Tumors" ], "interventions": [ { "name": "JNJ-95437446", "type": "DRUG" }, { "name": "Amivantamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2025-07-15", "completion_date": "2028-04-24", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-16T09:56:24.761Z", "location_count": 4, "location_summary": "Sarasota, Florida • New York, New York • Nashville, Tennessee + 1 more", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07107230" }, { "nct_id": "NCT01576666", "title": "Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Dose Escalation", "Safety", "Preliminary Efficacy", "Advanced Solid Tumors", "Metastatic Breast Cancer", "Advanced Pancreatic Adenocarcinoma", "Metastatic Colorectal Cancer", "Recurrent Glioblastoma Multiforme", "Gastric Cancer", "Gastroesophageal Junction Cancer", "Triple Negative Metastatic Breast Cancer", "Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer" ], "interventions": [ { "name": "LDE225", "type": "DRUG" }, { "name": "BKM120", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2012-07", "completion_date": "2015-04", "has_results": false, "last_update_posted_date": "2020-12-19", "last_synced_at": "2026-10-16T09:56:24.761Z", "location_count": 13, "location_summary": "Los Angeles, California • San Francisco, California • Tampa, Florida + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01576666" } ] }